NIPER Signs MoU with Boehringer Ingelheim India to Enhance Pharmaceutical Education & ResearchOn February 21, 2026, the National Institute of Pharmaceutical Education and Research (NIPER), Raebareli(Uttar Pradesh, UP), including its Centre of Excellence for Novel Drug Delivery Systems (CoE-NDDS), signed a Memorandum of Understanding (MoU) with Boehringer Ingelheim India Private Limited to enhance pharmaceutical education, research collaboration, and innovation.
- During the event, Cohort 2 of Alliance for Medical Research, Innovation, Translation & Value Acceleration (AMRITVA) was also launched to strengthen India’s innovation ecosystem.
Key Details:
Objective: The MoU will support curriculum enhancement aligned with industry needs, along with guest lectures, expert interactions, and short-term training programmes and workshops to enhance practical learning and industry exposure for students.
About AMRITVA Cohort 2:
Sponsored Advertisement
- Research Commercialization: Five innovators have been selected under Cohort 2 for grant support to help commercialize their research. It includes three faculty-led projects and two research scholar-led projects.
- Implementation: AMRITVA is implemented by the Startup Incubation and Innovation Centre (SIIC), Indian Institute of Technology (IIT) Kanpur (UP), in partnership with NIPER, Raebareli.
No comments yet. Be the first!